The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways.
Jungang ChenLu DaiSamantha KendrickSteven R PostZhiqiang QinPublished in: Antimicrobial agents and chemotherapy (2022)
Recently, remdesivir and molnupiravir were approved for treating COVID-19 caused by SARS-CoV-2 infection. However, little is known about the impact of these drugs on other viruses preexisted in COVID-19 patients. Here we report that remdesivir but not molnupiravir induced lytic reactivation of Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV), two major oncogenic herpesviruses. Remdesivir induced mature virion production from latently infected cells. Mechanistic studies showed that remdesivir induced KSHV and EBV reactivation by regulating several intracellular signaling pathways.
Keyphrases
- epstein barr virus
- sars cov
- high glucose
- diffuse large b cell lymphoma
- coronavirus disease
- diabetic rats
- signaling pathway
- drug induced
- induced apoptosis
- transcription factor
- oxidative stress
- respiratory syndrome coronavirus
- emergency department
- reactive oxygen species
- cell proliferation
- cell cycle arrest
- electronic health record
- case control
- genetic diversity